Dr. Susan SS Hue obtained her medical degree from the National University of Singapore (NUS) and her Ph.D from Imperial College London, U.K. in 2009.  She underwent her specialty training in anatomical pathology and became a Fellow of The Royal College of Pathologists of Australasia (FRCPA) in 2015. She is currently working as a certified histopathologist in National University Hospital (NUH), Singapore, and has active interests in haematolymphoid and soft tissue pathology.  Other than histopathology reporting, Dr. Hue also holds appointments in Department of Laboratory Medicine for flow cytometry reporting and IMCB, A*STAR as a Research Clinician. Her research interests include developing strategies for enhanced morpho-molecular diagnostics using computational imaging tools and miRNA profiling in the classification of lymphoma, soft tissue, breast, prostate and endometrial cancers. Dr. Hue works extensively with research groups and companies in the fields of digital pathology, computer-aided image analysis, multispectral imaging, and miRNA-based diagnostics.

Recently, Dr. Hue’s work on DLBCL biology has led her and her team to the basic laboratory investigative work on CD47-mediated mechanisms in DLBCL treatment resistance. Aberrant activation of CD47 on cancer cells has been implicated as an important resistance mechanism to R-CHOP treatment and targeting the CD47-SIRPa “don’t-eat-me” innate immune checkpoint has shown promising anti-cancer effects in patients with relapsed/refractory (R/R) DLBCL. Little is, however, understood about CD47’s biological effects beyond the mediation of immune evasion. We hypothesise that beyond its immune-related function, CD47 overexpression/activation may also regulate other pro-tumorigenic processes in DLBCL cells. Insights into these non-immune effects of CD47 in DLBCL cancer cells would expand our understanding of the repertoire of possible cellular effects of anti-CD47 therapy and pave the way for synergistic use of existing targeted therapies for treatment of R/R DLBCL.